Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder

Clinical Therapeutics

Volumn 35, Issue 11, 2013, Pages 1744-1751

  Chancellor, Michael B ^a   Migliaccio Walle, Kristen ^b   Bramley, Thomas J ^b   Chaudhari, Sham L ^b   Corbell, Catherine ^c   Globe, Denise ^c  

^a BEAUMONT HOSPITAL   (United States)

^b XCENDA   (United States)

^c ALLERGAN INC   (United States)

Author keywords

anticholinergic medication; overactive bladder; persistence; resource utilization; treatment failure

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; FESOTERODINE; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

ADULT; ARTICLE; BLADDER DISEASE; COHORT ANALYSIS; COMORBIDITY; DRUG FORMULATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GEL; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; OVERACTIVE BLADDER; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SYMPTOM; TREATMENT FAILURE; TREATMENT OUTCOME; URINE INCONTINENCE;

ANTICHOLINERGIC MEDICATION; OVERACTIVE BLADDER; PERSISTENCE; RESOURCE UTILIZATION; TREATMENT FAILURE;

ADULT; AGED; CHOLINERGIC ANTAGONISTS; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; TREATMENT FAILURE; URINARY BLADDER, OVERACTIVE; YOUNG ADULT;

EID: 84887944641     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.08.017     Document Type: Article

References (16)

1. S.J. Moon, Y.T. Kim, and T.Y. Lee The influence of an overactive bladder on falling: a study of females aged 40 and older in the community Int Neurourol J 15 2011 41 47
2. K.S. Coyne, C.C. Sexton, and J.A. Bell The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL Neurourol Urodyn 32 2013 230 237
3. A.O. D'Souza, M.J. Smith, and L.A. Miller Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan J Manag Care Pharm 14 2008 291 301
4. D.C. Malone, and G.J. Okano Treatment of urge incontinence in Veterans Affairs medical centers Clin Ther 21 1999 867 877
5. R.J. Baigrie, J.P. Kelleher, D.P. Fawcett, and A.W. Pengelly Oxybutynin: is it safe? Br J Urol 62 1988 319 322
6. Y.F. Yu, M.B. Nichol, A.P. Yu, and J. Ahn Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program Value Health 8 2005 495 505
7. F.T. Shaya, S. Blume, and A. Gu Persistence with overactive bladder pharmacotherapy in a Medicaid population Am J Manag Care 11 Suppl 4 2005 S121 S129
8. S. Varadharajan, Z. Jumadilova, P. Girase, and D.A. Ollendorf Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder Am J Manag Care 11 Suppl 4 2005 S140 S149
9. R. Balkrishnan, M.J. Bhosle, F.T. Camacho, and R.T. Anderson Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study J Urol 175 2006 1067 1072
10. J. Yeaw, J.S. Benner, and J.G. Walt Comparing adherence and persistence across 6 chronic medication classes J Manag Care Pharm 15 2009 728 740
11. E.A. Gormley, D.J. Lightner, and K.L. Burgio Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline J Urol 188 Suppl 6 2012 2455 2463
12. E.M. Pelletier, V. Vats, and J.Q. Clemens Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder Am J Manag Care 15 Suppl 4 2009 A108 A114
13. J.S. Benner, M.B. Nichol, and E.S. Rovner Patient-reported reasons for discontinuing overactive bladder medication BJU Int 105 2009 1276 1282
14. U.B. Campbell, P. Stang, and R. Barron Survey assessment of continuation of and satisfaction with pharmacological treatment for urinary incontinence Value Health 11 2008 726 732
15. N. Buser, S. Ivic, and T.M. Kessler Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analysis Euro Urol 62 2012 1040 1060
16. K.S. Lee, Y.S. Lee, and J.C. Kim Patient-reported goal achievement after antimuscarinic treatment in patients with overactive bladder symptoms Int J Clin Pract 66 2012 663 670